Pfizer Recalls Subpotent Levoxyl Levothyroxine Sodium Tablets
Pfizer is recalling 134 bottles of Levoxyl (levothyroxine sodium) 175 mcg tablets due to confirmed subpotency. The product was distributed nationwide and in Puerto Rico.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which indicates a situation where use of the product may cause temporary or medically reversible adverse health consequences. The source identifies the hazard as confirmed subpotency (out-of-specification assay) but does not report any illnesses, injuries, or deaths.
Plain-English summary
Pfizer is recalling 134 1000-count bottles of Levoxyl (levothyroxine sodium) tablets, 175 mcg, NDC 60793-859-10. The recall was initiated because stability testing confirmed the product was out-of-specification for assay, meaning the tablets are subpotent and contain less than the labeled amount of active ingredient.
The affected product, Lot # 24W07, with an expiration date of 11/30/2026, was distributed in the United States and Puerto Rico. Levoxyl is a prescription medication used to treat hypothyroidism.
Consumers with this specific lot of Levoxyl should stop using it and contact their healthcare provider or pharmacist for guidance on obtaining a replacement or alternative treatment.
The recalled product
- Product
- LEVOXYL (LEVOTHYROXINE SODIUM)
- Brand
- LEVOXYL
- Manufacturer
- Pfizer
- Category
- Drug — Prescription Drug
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 24W07
- Exp: 11/30/2026
UPCs (11)
- 0360793856018
- 0360793850016
- 0360793852010
- 0360793851013
- 0360793857015
- 0360793853017
- 0360793854014
- 0360793858012
- 0360793855011
- 0360793859019
- 0360793860015
Distribution
Related recalls
Same brand · LEVOXYL
- SeverePfizer Recalls Levoxyl Tablets Due to Subpotent Drug Levels
FDA (Drugs) · 2026-10-28
- HighLevoxyl 50 microgram levothyroxine tablets recalled as a subpotent drug
FDA (Drugs) · 2025-08-20
- ModerateCardinal Health Recalls LEVOXYL Tablets Due to Temperature Excursions
FDA (Drugs) · 2021-06-02
- SeverePfizer Recalls Levoxyl Levothyroxine Sodium Tablets Due to Superpotency
FDA (Drugs) · 2018-12-26
- SeverePfizer Recalls LEVOXYL Levothyroxine Sodium Tablets Due to Superpotency
FDA (Drugs) · 2016-11-30
Same manufacturer · Pfizer
See all →- SeverePfizer Recalls Dopamine Hydrochloride Injection Due to Sterility Concerns
FDA (Drugs) · 2026-09-23
- SevereDrug recall: Bleomycin injection vials recalled due to glass contamination
FDA (Drugs) · 2024-01-31
- SeverePfizer Recalls Daptomycin Injection Due to Microbial Contamination
FDA (Drugs) · 2018-08-08
- HighPfizer Recalls PureSilk Shave Gel for Women Due to Rupture Risk
CPSC · 1996-07-02
Same hazard · subpotency
See all →- ModerateGood Neighbor Pharmacy Earwax Removal Drug Recalled for Low Potency
FDA (Drugs) · 2026-07-22
- ModerateNystatin Cream Recall Due to Low Potency Test Results
FDA (Drugs) · 2026-07-22
- ModerateFoster & Thrive Carbamide Peroxide 6.5% Recalled for Subpotent Strength
FDA (Drugs) · 2026-07-22
- ModerateLeader Carbamide Peroxide Earwax Removal Kit Recalled for Subpotency
FDA (Drugs) · 2026-07-22
- ModerateMeijer Earwax Removal Kit Recalled for Subpotent Active Ingredient
FDA (Drugs) · 2026-07-22
Similar recalls
- SeverePfizer Recalls Levoxyl Tablets Due to Subpotent Drug Levels
FDA (Drugs) · 2026-10-28
- SeverePfizer Recalls Levoxyl Levothyroxine Sodium Tablets Due to Superpotency
FDA (Drugs) · 2018-12-26
- HighLevoxyl 50 microgram levothyroxine tablets recalled as a subpotent drug
FDA (Drugs) · 2025-08-20
- HighLevoxyl Levothyroxine Sodium Tablets Recalled for Low Potency
FDA (Drugs) · 2013-05-29
- ModerateLevoxyl Tablets Recalled for Low Potency at Expiry
FDA (Drugs) · 2013-05-29
- ModerateLevoxyl Levothyroxine Sodium Tablets Recalled for Subpotency
FDA (Drugs) · 2013-05-29